In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Benefit of primary prophylactic ICD-therapy in nonischemic compared to ischemic cardiomyopathy with and without cardiac resynchronization therapy

Session Poster session 3

Speaker Thomas Kleemann

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : Poster Session
  • FP Number : P1526

Authors : T Kleemann (Ludwigshafen,DE), E Lampropoulou (Ludwigshafen,DE), M Strauss (Ludwigshafen,DE), K Kouraki (Ludwigshafen,DE), N Werner (Ludwigshafen,DE), R Zahn (Ludwigshafen,DE)

15 views

Authors:
T Kleemann1 , E Lampropoulou1 , M Strauss1 , K Kouraki1 , N Werner1 , R Zahn1 , 1Medizinische Klinik B, Klinikum Ludwigshafen - Ludwigshafen - Germany ,

Citation:

Background: After the results of the Danish trial the benefit of primary prophylactic implantable cardioverter defibrillator (ICD) therapy with and without cardiac resynchronization therapy (CRT) in nonischemic cardiomyopathy (CMP) is questionable. Aim of the study was to evaluate the benefit of primary prophylactic ICD therapy with and without CRT in nonischemic compared to ischemic CMP. Methods: A total of 1188 consecutive patients of a prospective single-centre ICD-registry were analyzed who underwent ICD implantation for primary prevention of sudden cardiac death between 1996 and 2017. Patients were divided into four groups: ischemic CMP without CRT (ICM, n = 460) or with CRT (ICM-CRT, n = 231) and nonischemic CMP without CRT (NICM, n = 241) or with CRT (NICM-CRT, n = 256). The benefit of ICD therapy was defined as the occurrence of appropriate ICD therapy for ventricular tachyarrhythmias during follow-up. Results: After 10 years of ICD therapy the occurrence of ICD-terminated ventricular tachyarrhythmias was not different between all four groups.

Conclusions: About half of ICD-patients had an appropriate ICD therapy during a follow-up of 10 years. The incidence of ICD terminated ventricular tachyarrhythmias was not different between ICM and NICM patients with and without CRT-therapy.

Figure 1: Kaplan-Meier curves for the incidence of ICD-terminated ventricular tachyarrhythmias



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are